查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
精神益生菌市場 - 2018-2028年全球行業規模、佔有率、趨勢、競爭、機會和預測，按精神藥物、形式、應用、地區和競爭細分
市場調查報告書
商品編碼
1321048

精神益生菌市場 - 2018-2028年全球行業規模、佔有率、趨勢、競爭、機會和預測，按精神藥物、形式、應用、地區和競爭細分

Psychobiotics Market - Global Industry Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028 Segmented By Psychotropic Agent, By Form, By Application, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 110 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

預計全球精神益生菌市場將在2024-2028年預測期內實現非凡成長。市場的成長可歸因於人們對壓力、焦慮和睡眠障礙等心理健康問題的日益關注。根據2019年全球疾病、傷害和危險因素負擔研究 (GBD)，焦慮症和抑鬱症是兩種最使人喪失能力的精神疾病，列2019年全球疾病負擔的前 25 名主要原因。對於全球範圍內的男女來說，這一負擔都是沉重的。也許更重要的是，儘管有強力的證據表明治療可以減輕其影響，但尚未觀察到這兩種疾病的全球患病率或負擔有所下降。此外，COVID-19 的突然爆發以及2020-2021年全球不同國家為遏制該病毒而實施的封鎖增加了人們的心理健康問題。

對益生菌治療焦慮和抑鬱的需求不斷增加

透過影響微生物-腸-腦軸，益生菌可以對情緒和宿主健康產生影響。壓力、焦慮和抑鬱都包括情緒的逐漸淡化。焦慮是對壓力的一種反應，但如果持續存在並受到不當治療，可能會發展成更嚴重的精神疾病，例如抑鬱症。壓力通常來自各種對身體或情感要求較高的事件，以及對緊急情況的短暫反應。許多研究發現人們的焦慮和抑鬱之間存在微妙的聯繫。根據澳洲的資料，28%具有臨床顯著焦慮的患者還患有抑鬱症，大約 57%的抑鬱症患者還患有焦慮症。

根據一些研究，已證明腸道菌群在情緒調節中發揮著積極作用，並且益生菌具有廣泛的用途。一些研究表明，患有重度抑鬱症的受試者中變形菌門、擬桿菌門和放線菌門的水平增加，而厚壁菌門的數量顯著減少。益生菌對中樞神經系統活動和行為有多種影響。首先，一些局部細菌可以誘導宿主細胞產生神經遞質，包括血清素、多巴胺和 GABA。此外，微生物可以改變大腦神經遞質受體的表達。透過引起抗炎細胞因子的增加和促炎細胞因子的減少（一種與控制腸道通透性相關的模式），益生菌還有助於減少全身炎症。

鑑於益生菌有益於精神疾病，研究益生菌在治療壓力、焦慮和抑鬱等精神健康疾病中的應用的臨床試驗數量也在激增。因此，這將進一步有助於未來幾年全球精神益生菌市場的擴張。

焦慮和抑鬱病例激增

最常影響人們的兩種精神疾病是抑鬱症和焦慮症。抑鬱症是情緒障礙的主要類型之一，其特徵是情緒不佳和興趣喪失，常常伴有內疚、絕望、食慾不振和失眠。焦慮是一種緊張、擔憂和恐懼的感覺，以及沒有明確客觀原因的心悸、顫抖以及消化、呼吸和循環系統問題等身體變化。根據世界衛生組織 (WHO) 的估計，2015年，焦慮症的患病率預計為 3.6%，抑鬱症的患病率預計將達到 4.4%。

COVID-19 大流行還對世界各地患者的心理健康產生了最嚴重的影響。根據The Lancet發表的一項研究，全球男女焦慮症的發病率均增加了 25.6%。抑鬱症患病率增加了 27.6%。這兩種疾病的患病率在女性中明顯高於男性。女性抑鬱症患病率增加了 29.8%，而女性焦慮症患病率增加了 27.9%，男性增加了 21.7%。

消費者意識不斷提高

預計該市場的成長也將受到精神益生菌改善身體一般過程（包括消費者消化）的能力的推動。由於精神益生菌學能夠滿足胃腸道和免疫系統等特定消費者需求，以及產品開發的最新進展，預計需求也會增加。

Kerry Group 2019年對2,100 名具有健康意識的美國人進行的一項全球民意調查顯示，62%的受訪者知道什麼是益生菌，32%的受訪者在過去六個月內使用過益生菌。 79%了解益生菌的美國人表示，改善消化系統健康是他們在產品中尋求的最重要的健康益處。

此外，製造商投入大量精力開發具有新形式、飲食要求和包裝的創新精神益生菌相關產品。由於製造商推出純素和無麩質精神藥物產品，具有健康意識和純素食的消費者對精神藥物的需求不斷增加。因此，越來越多的人在生活中採用益生菌來改善和健康的生活方式。這可能會在預測的幾年內擴大精神益生菌產業。

可用的客製化：

根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。本報告可以使用以下自定義選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第1章：產品概述

  • 市場定義
  • 市場範圍
    • 涵蓋的市場
    • 研究年份
    • 主要市場細分

第2章：研究方法

  • 研究目的
  • 基線方法
  • 主要行業合作夥伴
  • 主要協會和二手資料來源
  • 預測方法
  • 資料三角測量和驗證
  • 假設和限制

第3章：執行摘要

  • 市場概況
  • 主要市場細分概述
  • 主要市場參與者概述
  • 重點地區/國家概況
  • 市場促進因素、挑戰、趨勢概述

第4章：客戶之聲

  • 品牌意識
  • 首選購買方式
  • 導致精神疾病的主要因素
  • 對精神抗生素消費的意願
  • 消費後常見的心理影響

第5章：臨床試驗分析

  • 進行的臨床試驗
  • 已完成的臨床試驗
  • 終止的臨床試驗
  • 按開發階段分類的管道細分
  • 按狀態分類的管道細分
  • 按研究應用分類的管道細分
  • 按地區分類的管道細分
  • 臨床試驗熱圖

第6章：專利分析

第7章：全球精神抗生素市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市場佔有率及預測
    • 按精神藥物（鏈球菌、雙歧桿菌、乳酸菌、梭菌等）
    • 按形式（粉末、液體/流體、片劑、其他）
    • 按應用（壓力管理、情緒健康和情緒提升、抑鬱、焦慮、睡眠問題等）
    • 按地區
    • 按公司分類 (2022)
  • 產品市場地圖
    • 透過精神藥物
    • 按形式
    • 按申請
    • 按地區
  • 定價分析

第8章：北美精神抗生素市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市場佔有率及預測
    • 按精神藥物（鏈球菌、雙歧桿菌、乳酸菌、梭菌等）
    • 按形式（粉末、液體/流體、片劑、其他）
    • 按應用（壓力管理、情緒健康和情緒提升、抑鬱、焦慮、睡眠問題等）
    • 按國家/地區
  • 定價分析
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第9章：歐洲精神抗生素市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市場佔有率及預測
    • 按精神藥物（鏈球菌、雙歧桿菌、乳酸菌、梭菌等）
    • 按形式（粉末、液體/流體、片劑、其他）
    • 按應用（壓力管理、情緒健康和情緒提升、抑鬱、焦慮、睡眠問題等）
    • 按國家/地區
  • 定價分析
  • 歐洲：國家分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙
    • 瑞典
    • 波蘭
    • 斯洛伐克

第10章：亞太地區精神抗生素市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市場佔有率及預測
    • 按精神藥物（鏈球菌、雙歧桿菌、乳酸菌、梭菌等）
    • 按形式（粉末、液體/流體、片劑、其他）
    • 按應用（壓力管理、情緒健康和情緒提升、抑鬱、焦慮、睡眠問題等）
    • 按國家/地區
  • 定價分析
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 馬來西亞
    • 新加坡

第11章：南美洲精神抗生素市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市場佔有率及預測
    • 按精神藥物（鏈球菌、雙歧桿菌、乳酸菌、梭菌等）
    • 按形式（粉末、液體/流體、片劑、其他）
    • 按應用（壓力管理、情緒健康和情緒提升、抑鬱、焦慮、睡眠問題等）
    • 按國家/地區
  • 定價分析
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第12章：中東和非洲精神抗生素市場展望

  • 市場規模及預測
    • 按價值和數量
  • 市場佔有率及預測
    • 按精神藥物（鏈球菌、雙歧桿菌、乳酸菌、梭菌等）
    • 按形式（粉末、液體/流體、片劑、其他）
    • 按應用（壓力管理、情緒健康和情緒提升、抑鬱、焦慮、睡眠問題等）
    • 按國家/地區
  • 定價分析
  • MEA：國家分析
    • 南非精神益生菌
    • 沙烏地阿拉伯精神益生菌
    • 阿拉伯聯合大公國精神益生菌

第13章：市場動態

  • 促進因素
    • 增加益生菌的使用來治療焦慮和抑鬱
    • 焦慮和抑鬱患者激增
    • 青少年自我診斷、自我治療傾向
  • 挑戰
    • 對身體健康的不利影響
    • 內分泌和代謝副作用
    • 發展中國家和欠已開發國家不可用

第14章：市場趨勢與發展

  • 臨床試驗數量不斷增加
  • 競爭加劇和即將到來的創新
  • 併購

第15章：競爭格局

  • 商業概覽
  • 公司概況
  • 產品與服務
  • 財務（據報導）
  • 最近的發展
  • SWOT分析
    • InnovixLabs
    • Bened Biomedical Co., Ltd
    • Nutrimmun GmbH
    • Kerry Group Plc.
    • Sabinsa Corporation
    • Lallemand Health Solutions Inc.
    • DuPont de Nemours, Inc.
    • Uplift Food Pty Ltd.
    • Nature's Bounty Co. Ltd.
    • BioGaia Group
    • The Life Extension Foundation
    • Lifted Naturals

第16章：戰略建議

簡介目錄
Product Code: 7678

Global Psychobiotics market is projected to accomplish extraordinary growth in the forecast period, 2024-2028. The market growth can be attributed to the rising concerns about mental health problems such as stress, anxiety, and sleep disorders, among others. According to the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019, anxiety and depression disorders were the two most incapacitating mental diseases, ranking among the top 25 primary causes of disease burden globally in 2019. This burden was heavy across the board, for both sexes, across the globe. Perhaps more crucially, despite strong evidence of therapies that lessen their impact, no decline in either disorder's global prevalence or burden has been observed. Additionally, the sudden outbreak of COVID-19 and the imposition of lockdown to curb the virus in 2020-2021 across different countries around the globe has increased mental health issues among the population.

A unique category of probiotics known as Psychobiotics helps people maintain their mental health. Psychobiotics capacity to create or encourage the formation of neurotransmitters, short-chain fatty acids, enteroendocrine hormones, and anti-inflammatory cytokines sets them apart from typical probiotics. Due to their therapeutic potential, Psychobiotics have a wide range of uses, from reducing stress and improving mood to being an adjuvant in the treatment of many neurodevelopmental and neurodegenerative illnesses. The families of Lactobacilli, Streptococci, Bifidobacteria, Escherichia, and Enterococci include the common psychobiotic bacteria. Although there are not many products available in the market, health-conscious people are making good use of the available psychobiotics and are including them in their daily food routines, thereby amplifying the growth of the global psychobiotic market in the future.

Increasing Demand for Probiotics to Treat Anxiety and Depression

By influencing the microbial-gut-brain axis, probiotics can have an impact on mood and host health. Stress, anxiety, and depression all involve the gradual dilution of emotions. Anxiety is a response to stress, but it can develop into more serious mental diseases like depression if it persists and is mistreated. Stress typically results from a variety of events that are physically or emotionally demanding, as well as from brief responses to urgent circumstances. Numerous studies have discovered a nuanced connection between anxiety and depression in people. According to Australian data, 28% of patients with clinically significant anxiety also had depression, and around 57% of those with depression also had comorbid anxiety.

Based on some research held, it has been proven that the intestinal flora plays an active role in mood regulation and that probiotics find their use in extended applications. Some studies indicate that levels of Proteobacteria, Bacteroidetes, and Actinobacteria were increased in subjects with major depressive disorders, whereas the amounts of Firmicutes decreased significantly. Probiotics have a variety of effects on CNS activity and behavior. First, some localized bacteria can induce the production of neurotransmitters, including serotonin, dopamine, and GABA, by the host's cells. Additionally, microorganisms can change the expression of brain neurotransmitter receptors. By causing an increase in anti-inflammatory cytokines and a decrease in pro-inflammatory cytokines-a pattern connected to the control of intestinal permeability-probiotics also assist in reducing systemic inflammation.

Given the fact that probiotics benefit psychiatric disorders, the number of clinical trials investigating the applications of probiotics in treating mental health disorders such as stress, anxiety, and depression has also proliferated. Hence, this is further aiding in the expansion of the global psychobiotic market in the upcoming years.

Surge in Cases of Anxiety and Depression

The two mental illnesses that affect people the most frequently are depression and anxiety disorders. One of the main types of mood disorders, depression, is characterized by poor mood and loss of interest, frequently accompanied by guilt, hopelessness, loss of appetite, and sleeplessness. Anxiety is a feeling of tension, concern, and fear, as well as bodily changes like palpitations, tremors, and problems with the digestive, respiratory, and circulatory systems that have no clear objective reasons. According to estimates from the World Health Organization (WHO), anxiety disorders were predicted to be 3.6% common, and depression was estimated to affect up to 4.4% of the world's population in 2015.

The COVID-19 pandemic also displayed its worst impacts on the mental health of patients across the world. According to a study published in The Lancet, anxiety disorders increased in incidence among both sexes globally by 25.6%. The prevalence of depressive illness increased by 27.6%. The increase in prevalence for both illnesses was noticeably greater in women than in men. Women had a 29.8% increase in the prevalence of depression, whereas anxiety prevalence was increased by 27.9% in women and by 21.7% in males.

Rising Consumer Awareness

The market's growth is also anticipated to be fueled by the psychobiotic capacity to improve the body's general processes, including consumer digestion. Demand is also projected to rise as a result of psychobiotics capacity to address particular consumer demands, such as gastrointestinal and immune systems, and recent advancements in product development.

According to a global poll conducted by Kerry Group in 2019 among 2,100 health-conscious Americans, 62% of respondents knew what probiotics were, and 32% had used them in the previous six months. 79% of Americans who were aware of probiotics responded that improving digestive health was the most important health benefit they look for in a product.

In addition, manufacturers are putting a lot of effort into developing innovative psychobiotic-related products with new forms, dietary requirements, and packaging. Due to the introduction of vegan and gluten-free psychobiotic products by manufacturers, the demand for psychobiotics is increasing among consumers who are health-conscious and vegan. Therefore, more and more people are adopting probiotics in their lives for an improved and healthy lifestyle. This is likely to augment the psychobiotic industry in the forecasted years.

Market Segmentation

Global psychobiotics market is segmented by psychotropic agent, form, application, region, and company. Based on psychotropic agents, the market can be segmented into streptococcus, bifidobacterium, lactobacillus, clostridium, and others. On the basis of form, the market can be categorized as powder, liquid/fluid, tablets, and others. Based on application, the market can be fragmented into stress management, mood health & mood upliftment, depression, anxiety, sleep problems, and others.

Company Profiles

Some of the major players operating in the global psychobiotics market are InnovixLabs, Bened Biomedical Co., Ltd, Nutrimmun GmbH, Kerry Group Plc., Sabinsa Corporation, Lallemand Health Solutions Inc., DuPont de Nemours, Inc., Uplift Food Pty Ltd., Nature's Bounty Co. Ltd., BioGaia Group, The Life Extension Foundation, and Lifted Naturals.

Report Scope

In this report, global psychobiotics market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Psychobiotics Market, By Psychotropic Agent:

  • Streptococcus
  • Bifidobacterium
  • Lactobacillus
  • Clostridium
  • Others

Psychobiotics Market, By Form:

  • Powder
  • Liquid/Fluid
  • Tablets
  • Others

Psychobiotics Market, By Application:

  • Stress Management
  • Mood Health & Mood Upliftment
  • Depression
  • Anxiety
  • Sleep Problems
  • Others

Psychobiotics Market, By Region:

  • North America
    • United States
    • Mexico
    • Canada
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
    • Sweden
    • Poland
    • Slovakia
  • Asia-Pacific
    • China
    • India
    • South Korea
    • Japan
    • Australia
    • Taiwan
    • Malaysia
    • Singapore
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the global psychobiotics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

  • 4.1. Brand Awareness
  • 4.2. Preferred Mode of Purchase
  • 4.3. Major Factors Contributing to Mental Illness
  • 4.4. Willingness towards Psychobiotics Consumption
  • 4.5. Commonly Observed Psychological Effect Post Consumption

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Patents Analysis

7. Global Psychobiotics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 7.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 7.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 7.2.4. By Region
    • 7.2.5. By Company (2022)
  • 7.3. Product Market Map
    • 7.3.1. By Psychotropic Agent
    • 7.3.2. By Form
    • 7.3.3. By Application
    • 7.3.4. By Region
  • 7.4. Pricing Analysis

8. North America Psychobiotics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 8.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 8.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 8.2.4. By Country
  • 8.3. Pricing Analysis
  • 8.4. North America: Country Analysis
    • 8.4.1. United States Psychobiotics Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value & Volume
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Psychotropic Agent
        • 8.4.1.2.2. By Form
        • 8.4.1.2.3. By Application
      • 8.4.1.3. Pricing Analysis
    • 8.4.2. Mexico Psychobiotics Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value & Volume
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Psychotropic Agent
        • 8.4.2.2.2. By Form
        • 8.4.2.2.3. By Application
      • 8.4.2.3. Pricing Analysis
    • 8.4.3. Canada Psychobiotics Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value & Volume
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Psychotropic Agent
        • 8.4.3.2.2. By Form
        • 8.4.3.2.3. By Application
      • 8.4.3.3. Pricing Analysis

9. Europe Psychobiotics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 9.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 9.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 9.2.4. By Country
  • 9.3. Pricing Analysis
  • 9.4. Europe: Country Analysis
    • 9.4.1. France Psychobiotics Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value & Volume
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Psychotropic Agent
        • 9.4.1.2.2. By Form
        • 9.4.1.2.3. By Application
      • 9.4.1.3. Pricing Analysis
    • 9.4.2. Germany Psychobiotics Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value & Volume
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Psychotropic Agent
        • 9.4.2.2.2. By Form
        • 9.4.2.2.3. By Application
      • 9.4.2.3. Pricing Analysis
    • 9.4.3. United Kingdom Psychobiotics Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value & Volume
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Psychotropic Agent
        • 9.4.3.2.2. By Form
        • 9.4.3.2.3. By Application
      • 9.4.3.3. Pricing Analysis
    • 9.4.4. Italy Psychobiotics Market Outlook
      • 9.4.4.1. Market Size & Forecast
        • 9.4.4.1.1. By Value & Volume
      • 9.4.4.2. Market Share & Forecast
        • 9.4.4.2.1. By Psychotropic Agent
        • 9.4.4.2.2. By Form
        • 9.4.4.2.3. By Application
      • 9.4.4.3. Pricing Analysis
    • 9.4.5. Spain Psychobiotics Market Outlook
      • 9.4.5.1. Market Size & Forecast
        • 9.4.5.1.1. By Value & Volume
      • 9.4.5.2. Market Share & Forecast
        • 9.4.5.2.1. By Psychotropic Agent
        • 9.4.5.2.2. By Form
        • 9.4.5.2.3. By Application
      • 9.4.5.3. Pricing Analysis
    • 9.4.6. Sweden Psychobiotics Market Outlook
      • 9.4.6.1. Market Size & Forecast
        • 9.4.6.1.1. By Value & Volume
      • 9.4.6.2. Market Share & Forecast
        • 9.4.6.2.1. By Psychotropic Agent
        • 9.4.6.2.2. By Form
        • 9.4.6.2.3. By Application
      • 9.4.6.3. Pricing Analysis
    • 9.4.7. Poland Psychobiotics Market Outlook
      • 9.4.7.1. Market Size & Forecast
        • 9.4.7.1.1. By Value & Volume
      • 9.4.7.2. Market Share & Forecast
        • 9.4.7.2.1. By Psychotropic Agent
        • 9.4.7.2.2. By Form
        • 9.4.7.2.3. By Application
      • 9.4.7.3. Pricing Analysis
    • 9.4.8. Slovakia Psychobiotics Market Outlook
      • 9.4.8.1. Market Size & Forecast
        • 9.4.8.1.1. By Value & Volume
      • 9.4.8.2. Market Share & Forecast
        • 9.4.8.2.1. By Psychotropic Agent
        • 9.4.8.2.2. By Form
        • 9.4.8.2.3. By Application
      • 9.4.8.3. Pricing Analysis

10. Asia-Pacific Psychobiotics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value & Volume
  • 10.2. Market Share & Forecast
    • 10.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 10.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 10.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 10.2.4. By Country
  • 10.3. Pricing Analysis
  • 10.4. Asia-Pacific: Country Analysis
    • 10.4.1. China Psychobiotics Market Outlook
      • 10.4.1.1. Market Size & Forecast
        • 10.4.1.1.1. By Value & Volume
      • 10.4.1.2. Market Share & Forecast
        • 10.4.1.2.1. By Psychotropic Agent
        • 10.4.1.2.2. By Form
        • 10.4.1.2.3. By Application
      • 10.4.1.3. Pricing Analysis
    • 10.4.2. India Psychobiotics Market Outlook
      • 10.4.2.1. Market Size & Forecast
        • 10.4.2.1.1. By Value & Volume
      • 10.4.2.2. Market Share & Forecast
        • 10.4.2.2.1. By Psychotropic Agent
        • 10.4.2.2.2. By Form
        • 10.4.2.2.3. By Application
      • 10.4.2.3. Pricing Analysis
    • 10.4.3. South Korea Psychobiotics Market Outlook
      • 10.4.3.1. Market Size & Forecast
        • 10.4.3.1.1. By Value & Volume
      • 10.4.3.2. Market Share & Forecast
        • 10.4.3.2.1. By Psychotropic Agent
        • 10.4.3.2.2. By Form
        • 10.4.3.2.3. By Application
      • 10.4.3.3. Pricing Analysis
    • 10.4.4. Japan Psychobiotics Market Outlook
      • 10.4.4.1. Market Size & Forecast
        • 10.4.4.1.1. By Value & Volume
      • 10.4.4.2. Market Share & Forecast
        • 10.4.4.2.1. By Psychotropic Agent
        • 10.4.4.2.2. By Form
        • 10.4.4.2.3. By Application
      • 10.4.4.3. Pricing Analysis
    • 10.4.5. Australia Psychobiotics Market Outlook
      • 10.4.5.1. Market Size & Forecast
        • 10.4.5.1.1. By Value & Volume
      • 10.4.5.2. Market Share & Forecast
        • 10.4.5.2.1. By Psychotropic Agent
        • 10.4.5.2.2. By Form
        • 10.4.5.2.3. By Application
      • 10.4.5.3. Pricing Analysis
    • 10.4.6. Taiwan Psychobiotics Market Outlook
      • 10.4.6.1. Market Size & Forecast
        • 10.4.6.1.1. By Value & Volume
      • 10.4.6.2. Market Share & Forecast
        • 10.4.6.2.1. By Psychotropic Agent
        • 10.4.6.2.2. By Form
        • 10.4.6.2.3. By Application
      • 10.4.6.3. Pricing Analysis
    • 10.4.7. Malaysia Psychobiotics Market Outlook
      • 10.4.7.1. Market Size & Forecast
        • 10.4.7.1.1. By Value & Volume
      • 10.4.7.2. Market Share & Forecast
        • 10.4.7.2.1. By Psychotropic Agent
        • 10.4.7.2.2. By Form
        • 10.4.7.2.3. By Application
      • 10.4.7.3. Pricing Analysis
    • 10.4.8. Singapore Psychobiotics Market Outlook
      • 10.4.8.1. Market Size & Forecast
        • 10.4.8.1.1. By Value & Volume
      • 10.4.8.2. Market Share & Forecast
        • 10.4.8.2.1. By Psychotropic Agent
        • 10.4.8.2.2. By Form
        • 10.4.8.2.3. By Application
      • 10.4.8.3. Pricing Analysis

11. South America Psychobiotics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value & Volume
  • 11.2. Market Share & Forecast
    • 11.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 11.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 11.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 11.2.4. By Country
  • 11.3. Pricing Analysis
  • 11.4. South America: Country Analysis
    • 11.4.1. Brazil Psychobiotics Market Outlook
      • 11.4.1.1. Market Size & Forecast
        • 11.4.1.1.1. By Value & Volume
      • 11.4.1.2. Market Share & Forecast
        • 11.4.1.2.1. By Psychotropic Agent
        • 11.4.1.2.2. By Form
        • 11.4.1.2.3. By Application
      • 11.4.1.3. Pricing Analysis
    • 11.4.2. Argentina Psychobiotics Market Outlook
      • 11.4.2.1. Market Size & Forecast
        • 11.4.2.1.1. By Value & Volume
      • 11.4.2.2. Market Share & Forecast
        • 11.4.2.2.1. By Psychotropic Agent
        • 11.4.2.2.2. By Form
        • 11.4.2.2.3. By Application
      • 11.4.2.3. Pricing Analysis
    • 11.4.3. Colombia Psychobiotics Market Outlook
      • 11.4.3.1. Market Size & Forecast
        • 11.4.3.1.1. By Value & Volume
      • 11.4.3.2. Market Share & Forecast
        • 11.4.3.2.1. By Psychotropic Agent
        • 11.4.3.2.2. By Form
        • 11.4.3.2.3. By Application
      • 11.4.3.3. Pricing Analysis

12. Middle East and Africa Psychobiotics Market Outlook

  • 12.1. Market Size & Forecast
    • 12.1.1. By Value & Volume
  • 12.2. Market Share & Forecast
    • 12.2.1. By Psychotropic Agent (Streptococcus, Bifidobacterium, Lactobacillus, Clostridium, Others)
    • 12.2.2. By Form (Powder, Liquid/Fluid, Tablets, Others)
    • 12.2.3. By Application (Stress Management, Mood Health & Mood Upliftment, Depression, Anxiety, Sleep Problems, Others)
    • 12.2.4. By Country
  • 12.3. Pricing Analysis
  • 12.4. MEA: Country Analysis
    • 12.4.1. South Africa Psychobiotics Market Outlook
      • 12.4.1.1. Market Size & Forecast
        • 12.4.1.1.1. By Value & Volume
      • 12.4.1.2. Market Share & Forecast
        • 12.4.1.2.1. By Psychotropic Agent
        • 12.4.1.2.2. By Form
        • 12.4.1.2.3. By Application
      • 12.4.1.3. Pricing Analysis
    • 12.4.2. Saudi Arabia Psychobiotics Market Outlook
      • 12.4.2.1. Market Size & Forecast
        • 12.4.2.1.1. By Value & Volume
      • 12.4.2.2. Market Share & Forecast
        • 12.4.2.2.1. By Psychotropic Agent
        • 12.4.2.2.2. By Form
        • 12.4.2.2.3. By Application
      • 12.4.2.3. Pricing Analysis
    • 12.4.3. UAE Psychobiotics Market Outlook
      • 12.4.3.1. Market Size & Forecast
        • 12.4.3.1.1. By Value & Volume
      • 12.4.3.2. Market Share & Forecast
        • 12.4.3.2.1. By Psychotropic Agent
        • 12.4.3.2.2. By Form
        • 12.4.3.2.3. By Application
      • 12.4.3.3. Pricing Analysis

13. Market Dynamics

  • 13.1. Drivers
    • 13.1.1. Increased Use of Probiotics for Anxiety and Depression
    • 13.1.2. Surge in Subjects with Anxiety and Depression
    • 13.1.3. Tendency of Self-diagnosing and Self-medication amongst the Youth
  • 13.2. Challenges
    • 13.2.1. Detrimental Effects on Physical Health
    • 13.2.2. Endocrine and Metabolic Side Effects
    • 13.2.3. Unavailability in Developing Countries and Under-Developed Countries

14. Market Trends & Developments

  • 14.1. Increasing Number of Clinical Trials
  • 14.2. Increased Competition and Upcoming Innovations
  • 14.3. Mergers & Acquisitions

15. Competitive Landscape

  • 15.1. Business Overview
  • 15.2. Company Snapshot
  • 15.3. Products & Services
  • 15.4. Financials (As Reported)
  • 15.5. Recent Developments
  • 15.6. SWOT Analysis
    • 15.6.1. InnovixLabs
    • 15.6.2. Bened Biomedical Co., Ltd
    • 15.6.3. Nutrimmun GmbH
    • 15.6.4. Kerry Group Plc.
    • 15.6.5. Sabinsa Corporation
    • 15.6.6. Lallemand Health Solutions Inc.
    • 15.6.7. DuPont de Nemours, Inc.
    • 15.6.8. Uplift Food Pty Ltd.
    • 15.6.9. Nature's Bounty Co. Ltd.
    • 15.6.10. BioGaia Group
    • 15.6.11. The Life Extension Foundation
    • 15.6.12. Lifted Naturals

16. Strategic Recommendations